Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.

Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, Diniz MA, Spector N, Clay TM, Chen W, Morse MA, Lyerly HK.

Breast Cancer Res. 2018 Aug 9;20(1):90. doi: 10.1186/s13058-018-1023-x.

2.

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.

Crosby EJ, Wei J, Yang XY, Lei G, Wang T, Liu CX, Agarwal P, Korman AJ, Morse MA, Gouin K, Knott SRV, Lyerly HK, Hartman ZC.

Oncoimmunology. 2018 Jan 19;7(5):e1421891. doi: 10.1080/2162402X.2017.1421891. eCollection 2018.

3.

In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.

Osada T, Kaneko K, Gwin WR, Morse MA, Hobeika A, Pogue BW, Hartman ZC, Hughes PF, Haystead T, Lyerly HK.

Clin Cancer Res. 2017 Dec 15;23(24):7531-7542. doi: 10.1158/1078-0432.CCR-17-1453. Epub 2017 Oct 9.

PMID:
28993342
4.

An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Shuptrine CW, Ajina R, Fertig EJ, Jablonski SA, Kim Lyerly H, Hartman ZC, Weiner LM.

Cancer Immunol Immunother. 2017 Dec;66(12):1529-1544. doi: 10.1007/s00262-017-2047-2. Epub 2017 Aug 2.

PMID:
28770278
5.

Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.

Ren J, Gwin WR, Zhou X, Wang X, Huang H, Jiang N, Zhou L, Agarwal P, Hobeika A, Crosby E, Hartman ZC, Morse MA, H Eng K, Lyerly HK.

Oncoimmunology. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563. eCollection 2017.

6.

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.

Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PH.

Breast Cancer Res Treat. 2016 Aug;158(3):441-54. doi: 10.1007/s10549-016-3892-y. Epub 2016 Jul 8.

7.

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.

Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozcelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ.

Oncogene. 2016 Nov 24;35(47):6053-6064. doi: 10.1038/onc.2016.129. Epub 2016 May 9.

8.

Death-associated protein kinase 1 promotes growth of p53-mutant cancers.

Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH.

J Clin Invest. 2015 Jul 1;125(7):2707-20. doi: 10.1172/JCI70805. Epub 2015 Jun 15.

9.

Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

Barrott JJ, Hughes PF, Osada T, Yang XY, Hartman ZC, Loiselle DR, Spector NL, Neckers L, Rajaram N, Hu F, Ramanujam N, Vaidyanathan G, Zalutsky MR, Lyerly HK, Haystead TA.

Chem Biol. 2013 Sep 19;20(9):1187-97. doi: 10.1016/j.chembiol.2013.08.004. Epub 2013 Sep 12.

10.

Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.

Poage GM, Hartman ZC, Brown PH.

Cell Cycle. 2013 Sep 1;12(17):2705-6. doi: 10.4161/cc.25871. Epub 2013 Jul 30. No abstract available.

11.

Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.

Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH.

Cancer Res. 2013 Jun 1;73(11):3470-80. doi: 10.1158/0008-5472.CAN-12-4524-T. Epub 2013 Apr 30.

12.

A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF.

Science. 2012 Jan 20;335(6066):348-53. doi: 10.1126/science.1212728. Epub 2011 Dec 8.

13.

Increasing vaccine potency through exosome antigen targeting.

Hartman ZC, Wei J, Glass OK, Guo H, Lei G, Yang XY, Osada T, Hobeika A, Delcayre A, Le Pecq JB, Morse MA, Clay TM, Lyerly HK.

Vaccine. 2011 Nov 21;29(50):9361-7. doi: 10.1016/j.vaccine.2011.09.133. Epub 2011 Oct 12.

14.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

15.

HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.

Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS, Morse MA, Clay TM, Lyerly HK.

Cancer Res. 2011 Jul 1;71(13):4380-91. doi: 10.1158/0008-5472.CAN-11-0308. Epub 2011 Apr 25.

16.

Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Lyerly HK.

Immunol Res. 2011 Apr;49(1-3):235-47. doi: 10.1007/s12026-010-8186-6.

17.

Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.

Hartman ZC, Osada T, Glass O, Yang XY, Lei GJ, Lyerly HK, Clay TM.

Cancer Res. 2010 Sep 15;70(18):7209-20. doi: 10.1158/0008-5472.CAN-10-0905. Epub 2010 Sep 7.

18.

Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Seregin SS, Aldhamen YA, Appledorn DM, Hartman ZC, Schuldt NJ, Scott J, Godbehere S, Jiang H, Frank MM, Amalfitano A.

Blood. 2010 Sep 9;116(10):1669-77. doi: 10.1182/blood-2010-03-276949. Epub 2010 May 28.

19.

Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.

Seregin SS, Hartman ZC, Appledorn DM, Godbehere S, Jiang H, Frank MM, Amalfitano A.

J Innate Immun. 2010;2(4):353-9. doi: 10.1159/000284368. Epub 2010 Feb 11.

20.

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.

Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, Jones FR.

Cancer Immunol Immunother. 2010 Jul;59(7):1131-5. doi: 10.1007/s00262-010-0847-8. Epub 2010 Apr 2.

PMID:
20361185
21.

An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, Morse MA, Lyerly HK, Clay TM.

Clin Cancer Res. 2010 Mar 1;16(5):1466-77. doi: 10.1158/1078-0432.CCR-09-2549. Epub 2010 Feb 23.

22.

Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Osada T, Woo CY, McKinney M, Yang XY, Lei G, Labreche HG, Hartman ZC, Niedzwiecki D, Chao N, Amalfitano A, Morse MA, Lyerly HK, Clay TM.

Clin Cancer Res. 2009 Apr 15;15(8):2789-96. doi: 10.1158/1078-0432.CCR-08-2589. Epub 2009 Apr 7.

23.

Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.

Osada T, Yang XY, Hartman ZC, Glass O, Hodges BL, Niedzwiecki D, Morse MA, Lyerly HK, Amalfitano A, Clay TM.

Cancer Gene Ther. 2009 Sep;16(9):673-82. doi: 10.1038/cgt.2009.17. Epub 2009 Feb 20.

24.

The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.

Cohen TJ, Barrientos T, Hartman ZC, Garvey SM, Cox GA, Yao TP.

FASEB J. 2009 Jan;23(1):99-106. doi: 10.1096/fj.08-115931. Epub 2008 Sep 9.

25.

Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Hartman ZC, Appledorn DM, Serra D, Glass O, Mendelson TB, Clay TM, Amalfitano A.

Virology. 2008 May 10;374(2):453-67. doi: 10.1016/j.virol.2008.01.017. Epub 2008 Feb 15.

26.

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Hartman ZC, Appledorn DM, Amalfitano A.

Virus Res. 2008 Mar;132(1-2):1-14. Epub 2007 Nov 26. Review.

27.

Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM, Amalfitano A.

J Virol. 2007 Feb;81(4):1796-812. Epub 2006 Nov 22.

28.
29.

Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

Kiang A, Hartman ZC, Everett RS, Serra D, Jiang H, Frank MM, Amalfitano A.

Mol Ther. 2006 Oct;14(4):588-98. Epub 2006 Jun 2.

30.

Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.

Kiang A, Hartman ZC, Liao S, Xu F, Serra D, Palmer DJ, Ng P, Amalfitano A.

Mol Ther. 2006 Jan;13(1):127-34. Epub 2005 Oct 5.

Supplemental Content

Loading ...
Support Center